Table 2.
Open in new tab

Virological and non-virological outcomes according to HIV coinfection

Outcome (N = 132)HCV-monoinfected
(N = 512)		HIV/HCV-coinfected (N = 132)P value
Discontinuation due to adverse events, n (%)0 (0)1 (0.8)0.049
Dropout, n (%)30 (5.9)5a (3.8)0.517
Viral breakthrough, n (%)0 (0)0 (0)—
Viral relapse, n (%)1 (0.2)1 (0.8)0.301
SVR ITT, n (%)487 (95.1)126 (95.5)1.000
Outcome (N = 132)HCV-monoinfected
(N = 512)		HIV/HCV-coinfected (N = 132)P value
Discontinuation due to adverse events, n (%)0 (0)1 (0.8)0.049
Dropout, n (%)30 (5.9)5a (3.8)0.517
Viral breakthrough, n (%)0 (0)0 (0)—
Viral relapse, n (%)1 (0.2)1 (0.8)0.301
SVR ITT, n (%)487 (95.1)126 (95.5)1.000

One patient with active drug use achieved SVR despite prematurely discontinuing treatment.

Table 2.
Open in new tab

Virological and non-virological outcomes according to HIV coinfection

Outcome (N = 132)HCV-monoinfected
(N = 512)		HIV/HCV-coinfected (N = 132)P value
Discontinuation due to adverse events, n (%)0 (0)1 (0.8)0.049
Dropout, n (%)30 (5.9)5a (3.8)0.517
Viral breakthrough, n (%)0 (0)0 (0)—
Viral relapse, n (%)1 (0.2)1 (0.8)0.301
SVR ITT, n (%)487 (95.1)126 (95.5)1.000
Outcome (N = 132)HCV-monoinfected
(N = 512)		HIV/HCV-coinfected (N = 132)P value
Discontinuation due to adverse events, n (%)0 (0)1 (0.8)0.049
Dropout, n (%)30 (5.9)5a (3.8)0.517
Viral breakthrough, n (%)0 (0)0 (0)—
Viral relapse, n (%)1 (0.2)1 (0.8)0.301
SVR ITT, n (%)487 (95.1)126 (95.5)1.000

One patient with active drug use achieved SVR despite prematurely discontinuing treatment.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close